Literature DB >> 2790809

Antitumor activity of indomethacin in mice bearing advanced colon 26 carcinoma compared with those with early transplants.

Y Tanaka1, T Tanaka, H Ishitsuka.   

Abstract

The antitumor activity of indomethacin (IND) was investigated in mice bearing advanced colon 26 adenocarcinoma compared with its early transplants. Treatment with 0.001% IND in drinking water retarded the growth of tumor when commenced at Day 1 after the tumor inoculation. The suppression of the tumor growth by IND continued up to 4 to 5 weeks as long as the size of the tumor remained small. On the other hand, IND given to mice bearing a large burden of the tumor at 2 weeks after the inoculation had facilitated the tumor growth. IND reduced tumor-associated PGE2 production in mice bearing either small or large burdens of the tumors. These results indicate that the antitumor activity of IND depends on tumor size and therefore is not simply associated with the reduction of PGE2 levels. We found that colon 26 caused changes in parameters reported for tumor cachexia, such as weight loss, wasting of muscle and adipose tissues and hypoglycemia, when it grew to around 1 g at 2-3 weeks after the tumor inoculation. IND given to the mice with large burdens of colon 26 alleviated the cachexia of the mice, resulting in the increase of the survival time even though the growth of the tumor had been facilitated. It is possible that IND affects the tumor growth and survival by reversing tumor-induced disorders in homeostasis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2790809

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Synergistic effect of indomethacin and bleomycin on tumor growth produced by activating antitumor immunity.

Authors:  R Matsushita; K Hattori; K Hayashi; H Iizasa; F Ichimura; E Nakashima
Journal:  Pharm Res       Date:  2001-02       Impact factor: 4.200

2.  Prevention of bleomycin-induced fibrosing alveolitis with indomethacin: stereological studies on rat lungs.

Authors:  G Mall; P Zimmermann; I Siemens; A Burkhardt; H F Otto
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

3.  Stimulation of decreased lipoprotein lipase activity in the tumor-bearing state by the antihyperlipidemic drug bezafibrate.

Authors:  K Nomura; Y Noguchi; A Matsumoto
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

Review 4.  Are cytokines possible mediators of cancer cachexia?

Authors:  Y Noguchi; T Yoshikawa; A Matsumoto; G Svaninger; J Gelin
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

5.  Pharmacological interference with tissue hypercatabolism in tumour-bearing rats.

Authors:  L Tessitore; P Costelli; F M Baccino
Journal:  Biochem J       Date:  1994-04-01       Impact factor: 3.857

6.  Role of NF-kappaB and cytokine in experimental cancer cachexia.

Authors:  Wei Zhou; Zhi-Wei Jiang; Jie Tian; Jun Jiang; Ning Li; Jie-Shou Li
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

7.  Effect of combined administration of a synthetic low-toxicity lipid A derivative, DT-5461a, and indomethacin in various experimental tumor models of colon 26 carcinoma in mice.

Authors:  T Jimbo; T Akimoto; A Tohgo
Journal:  Cancer Immunol Immunother       Date:  1995-01       Impact factor: 6.968

8.  Chemoprevention with phosphatidylcholine non-steroidal anti-inflammatory drugs in vivo and in vitro.

Authors:  Lenard M Lichtenberger; Tri Phan; Dexing Fang; Elizabeth J Dial
Journal:  Oncol Lett       Date:  2018-02-21       Impact factor: 2.967

9.  5'-Deoxy-5-fluorouridine improves cachexia by a mechanism independent of its antiproliferative action in colon 26 adenocarcinoma-bearing mice.

Authors:  H Eda; Y Tanaka; H Ishitsuka
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

10.  Humoral mediation for cachexia in tumour-bearing rats.

Authors:  L Tessitore; P Costelli; F M Baccino
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.